# Phase 2 alcoholism trials recruiting: 50 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials in phase 2 for alcoholism that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 alcoholism trials: 50 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/alcoholism

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 50
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941895 | Biphasic Effect of Alcohol on Pain | Yale University | Phase 2 | Not yet recruiting | Alcohol Use, Chronic Low-back Pain (cLBP), Alcohol Use Disorder (AUD), Quantitative Sensory Testing, Pain Alleviation | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941895) |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| November 3, 2026 | NCT07913542 | N-Acetylcysteine for Bipolar and Alcohol Use Disorders | Medical University of South Carolina | Phase 2 | Not yet recruiting | Bipolar Disorder, Alcohol Use Disorder | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913542) |
| September 28, 2026 | NCT07844720 | Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 | Recruiting | Alcohol Use Disorder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844720) |
| July 29, 2026 | NCT07734701 | Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734701) |
| July 14, 2026 | NCT07701928 | Daridorexant for People With Insomnia and Alcohol Use Disorder Study | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Alcohol Use Disorder, Insomnia | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701928) |
| July 2, 2026 | NCT07681869 | Effects of Nimodipine on Alcohol Drinking | Yale University | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681869) |
| April 15, 2026 | NCT07532252 | Daridorexant for Alcohol Use Disorder | Johns Hopkins University | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532252) |
| March 31, 2026 | NCT07503782 | OEA for Young Adults With Alcohol Use Disorder | Medical University of South Carolina | Phase 2 | Not yet recruiting | Alcohol Use Disorder (AUD) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503782) |
| March 5, 2026 | NCT07452146 | Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use | University of California, Los Angeles | Phase 2 | Not yet recruiting | Alcohol Use Disorder, Inflammatory Response, Craving | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07452146) |
| February 12, 2026 | NCT07405606 | Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | Centre for Addiction and Mental Health | Phase 2 | Recruiting | Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405606) |
| January 8, 2026 | NCT07325266 | Human Laboratory Study of Apremilast for Alcohol Use Disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | Recruiting | Alcohol Use Disorder, Alcohol Misuse | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325266) |
| December 29, 2025 | NCT07306078 | Methylphenidate and Response to Alcohol Cues | University of Florida | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07306078) |
| December 22, 2025 | NCT07296094 | Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder | Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296094) |
| December 18, 2025 | NCT07292519 | Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | South West Sydney Local Health District | Phase 2 | Not yet recruiting | Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292519) |
| December 12, 2025 | NCT07279558 | Cannabidiol and Alcohol Use Disorder Phenotypes | University of Colorado, Denver | Phase 2 | Recruiting | Alcohol Use Disorder | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279558) |
| November 25, 2025 | NCT07249554 | Combination Therapy for Alcohol Use Disorder | Johns Hopkins University | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249554) |
| October 9, 2025 | NCT07214207 | Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking | Ohio State University | Phase 2 | Recruiting | Alcohol Use Disorder | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214207) |
| August 12, 2025 | NCT07118618 | Probenecid Administration for Alcohol Craving and Consumption | Brown University | Phase 2 | Recruiting | Alcohol Use Disorder (AUD), Alcohol Consumption, Craving | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118618) |
| July 2, 2025 | NCT07046819 | Tirzepatide in MetALD | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | Recruiting | Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046819) |
| June 27, 2025 | NCT07040592 | Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Yale University | Phase 2 | Recruiting | Alcohol Use Disorder (AUD), HIV | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07040592) |
| June 19, 2025 | NCT07029529 | Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder | Yale University | Phase 2 | Recruiting | Alcohol Use Disorder | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029529) |
| May 29, 2025 | NCT06994338 | Tirzepatide for Alcohol Use Disorder | University of Southern California | Phase 2 | Recruiting | Alcohol Use Disorder, Obesity and Overweight, Alcohol | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994338) |
| May 14, 2025 | NCT06969937 | Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alcohol Abuse/Dependence, Alcohol Use Disorder (AUD), Alcoholism | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06969937) |
| April 22, 2025 | NCT06939088 | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06939088) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Yale University | 6 |
| University of Colorado, Denver | 2 |
| Johns Hopkins University | 2 |
| Brown University | 2 |
| Brigham and Women's Hospital | 2 |
| Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 2 |
| Medical University of South Carolina | 2 |
| Ohio State University | 2 |
| University of California, Los Angeles | 2 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2 |
| NYU Langone Health | 2 |
| University of Iowa | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Afasci Inc | 1 |
| University of Calgary | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Texas A&M University | 1 |
| The Mind Research Network | 1 |
| Centre for Addiction and Mental Health | 1 |
| South West Sydney Local Health District | 1 |
| Washington State University | 1 |
| University of Southern California | 1 |
| VA Connecticut Healthcare System | 1 |
| University of Florida | 1 |
| Indiana University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 37 |
| France | 2 |
| Canada | 2 |
| Switzerland | 2 |
| Denmark | 1 |
| Australia | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Nepalese restaurants in the United States](https://specstream.ai/data/businesses/nepalese-restaurants/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
